• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    PTC Therapeutics, Inc. (PTCT)

    7.42 Down 0.42(5.36%) Apr 29, 4:00PM EDT
    ProfileGet Profile for:
    PTC Therapeutics, Inc.
    100 Corporate Court
    South Plainfield, NJ 07080
    United States - Map
    Phone: 908-222-7000
    Fax: 908-222-7231
    Website: http://www.ptcbio.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7800 that is in Phase II clinical trials for the treatment of spinal muscular atrophy and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the company’s development programs include PTC596, which is in Phase I clinical trials to treat chemotherapy resistant cancers. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on PTC Therapeutics, Inc.

    Corporate Governance 
    PTC Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Stuart W. Peltz Ph.D., 56
    Co-Founder, Chief Exec. Officer and Exec. Director
    Dr. Allan Steven Jacobson Ph.D., 70
    Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating & Corp. Governance Committee
    Mr. Shane William Charles Kovacs , 42
    Chief Financial Officer, Head of Corp. Devel. and Exec. VP
    Dr. Neil Almstead Ph.D., 49
    Exec. VP of Research, Pharmaceutical Operations & Technology
    Mr. Mark Elliott Boulding , 55
    Chief Legal Officer and Exec. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders